Skip to content

Quick ratio at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
4.1×-5.5×
ALN
Alnylam PharmaceuticalsALNY
3.1×+0.1×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
18×+2.3×
Beam Therapeutics logo
Beam TherapeuticsBEAM
17×+8.2×
Vera Therapeutics logo
Vera TherapeuticsVERA
13.6×-14.0×
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
9.1×-0.2×

Other financials

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation

See full
Market cap$2.13B+106%
Enterprise value$2.08B+100%
P/S32.2×+9.5×

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

Where this comes from

Calculated from Intellia Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellia Therapeutics's quick ratio?
Intellia Therapeutics (NTLA) reported quick ratio of 6.1× in Q1 2026.
How has Intellia Therapeutics's quick ratio changed year-over-year?
Intellia Therapeutics's quick ratio increased by 24.6% year-over-year, from 4.9× to 6.1×.
What is the long-term trend for Intellia Therapeutics's quick ratio?
Over 5 years (2020 to 2025), Intellia Therapeutics's quick ratio has grown at a -11.9% compound annual growth rate (CAGR), from 9.6× to 5.1×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.